CRWV vs MRK: Which Is the Better Buy?
Side-by-side comparison of CoreWeave, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
CoreWeave, Inc. · Technology
$89.89
+24.6% upside to fair value
Med Conviction
Grade C+
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
CRWV has more upside to fair value
(+24.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWV |
MRK |
| Current Price |
$89.89 |
$113.87 |
| Fair Value Estimate |
$112.00 |
$100.14 |
| Upside to Fair Value |
+24.6%
|
-12.1%
|
| Market Cap |
$49.0B |
$281.2B |
| Forward P/E |
—
|
32.0x
|
| EV / EBITDA |
26.6x
|
17.3x
|
| Price / Sales |
7.9x
|
4.3x
|
| Price / FCF |
—
|
19.9x
|
| Revenue Growth YoY |
+111.6%
|
+4.3%
|
| Gross Margin |
69.4%
|
75.9%
|
| Operating Margin |
-2.6%
|
27.6%
|
| Return on Equity |
-33.5%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
-21.6%
|
5.02%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
CoreWeave is the leading neocloud, a GPU-specialized cloud infrastructure provider built to serve the compute-hungry demands of generative AI training and inference. Since its March 2025 IPO, revenue has scaled roughly 112% year over year to $2.08 billion in the first quarter of 2026, backed by a $99.4 billion contracted revenue backlog and marquee agreements with Microsoft, OpenAI, Meta, Anthrop…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
CRWV |
MRK |
| Zone Low |
$84.00 |
$75.11 |
| Zone High |
$95.00 |
$85.12 |
| In Buy Zone? |
Yes
|
No
|